 Connection
Peter Crooks to Nicotine
This is a "connection" page, showing publications Peter Crooks has written about Nicotine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.219 |
|
|
|
-
Zhang Z, Pivavarchyk M, Subramanian KL, Deaciuc AG, Dwoskin LP, Crooks PA. Novel bis-2,2,6,6-tetramethylpiperidine (bis-TMP) and bis-mecamylamine antagonists at neuronal nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2010 Feb 15; 20(4):1420-3.
Score: 0.312
-
Zheng F, Zheng G, Deaciuc AG, Zhan CG, Dwoskin LP, Crooks PA. Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the alpha4beta2* nicotinic acetylcholine receptor. J Enzyme Inhib Med Chem. 2009 Feb; 24(1):157-68.
Score: 0.292
-
Malkawi AH, Al-Ghananeem AM, de Leon J, Crooks PA. Nicotine exposure can be detected in cerebrospinal fluid of active and passive smokers. J Pharm Biomed Anal. 2009 Jan 15; 49(1):129-32.
Score: 0.286
-
Zhang Z, Zheng G, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2008 Nov 01; 18(21):5753-7.
Score: 0.285
-
Zheng G, Sumithran SP, Deaciuc AG, Dwoskin LP, Crooks PA. Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2007 Dec 15; 17(24):6701-6.
Score: 0.268
-
Zheng G, Zhang Z, Pivavarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation. Bioorg Med Chem Lett. 2007 Dec 15; 17(24):6734-8.
Score: 0.267
-
Ayers JT, Xu R, Dwoskin LP, Crooks PA. A general procedure for the enantioselective synthesis of the minor tobacco alkaloids nornicotine, anabasine, and anatabine. AAPS J. 2005 Oct 31; 7(3):E752-8.
Score: 0.233
-
Papke RL, Zheng G, Horenstein NA, Dwoskin LP, Crooks PA. The characterization of a novel rigid nicotine analog with alpha7-selective nAChR agonist activity and modulation of agonist properties by boron inclusion. Bioorg Med Chem Lett. 2005 Sep 01; 15(17):3874-80.
Score: 0.231
-
Wooters TE, Smith AM, Pivavarchyk M, Siripurapu KB, McIntosh JM, Zhang Z, Crooks PA, Bardo MT, Dwoskin LP. bPiDI: a novel selective a6?2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol. 2011 May; 163(2):346-57.
Score: 0.085
-
Pivavarchyk M, Smith AM, Zhang Z, Zhou D, Wang X, Toyooka N, Tsuneki H, Sasaoka T, McIntosh JM, Crooks PA, Dwoskin LP. Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release. Eur J Pharmacol. 2011 May 11; 658(2-3):132-9.
Score: 0.084
-
Holtman JR, Crooks PA, Johnson-Hardy JK, Wala EP. The analgesic and toxic effects of nornicotine enantiomers alone and in interaction with morphine in rodent models of acute and persistent pain. Pharmacol Biochem Behav. 2010 Jan; 94(3):352-62.
Score: 0.077
-
Smith AM, Dhawan GK, Zhang Z, Siripurapu KB, Crooks PA, Dwoskin LP. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices. Biochem Pharmacol. 2009 Oct 01; 78(7):889-97.
Score: 0.076
-
Zheng F, McConnell MJ, Zhan CG, Dwoskin LP, Crooks PA. QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum. Bioorg Med Chem. 2009 Jul 01; 17(13):4477-85.
Score: 0.074
-
Dwoskin LP, Pivavarchyk M, Joyce BM, Neugebauer NM, Zheng G, Zhang Z, Bardo MT, Crooks PA. Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebr Symp Motiv. 2009; 55:31-63.
Score: 0.073
-
Middleton LS, Crooks PA, Wedlund PJ, Cass WA, Dwoskin LP. Nornicotine inhibition of dopamine transporter function in striatum via nicotinic receptor activation. Synapse. 2007 Mar; 61(3):157-65.
Score: 0.064
-
Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology. 2007 Mar; 52(3):755-63.
Score: 0.063
-
Wilkins LH, Miller DK, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of antagonists at alpha 4 beta 2* nicotinic acetylcholine receptors: inhibition of S(-)-nicotine-evoked 86Rb+ efflux from rat thalamic synaptosomes. AAPS J. 2006 Jan 13; 7(4):E922-30.
Score: 0.059
-
Huang X, Zheng F, Crooks PA, Dwoskin LP, Zhan CG. Modeling multiple species of nicotine and deschloroepibatidine interacting with alpha4beta2 nicotinic acetylcholine receptor: from microscopic binding to phenomenological binding affinity. J Am Chem Soc. 2005 Oct 19; 127(41):14401-14.
Score: 0.058
-
Sumithran SP, Crooks PA, Xu R, Zhu J, Deaciuc AG, Wilkins LH, Dwoskin LP. Introduction of unsaturation into the N-n-alkyl chain of the nicotinic receptor antagonists, NONI and NDNI: effect on affinity and selectivity. AAPS J. 2005 Aug 29; 7(1):E201-17.
Score: 0.058
-
Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett. 2004 Apr 19; 14(8):1863-7.
Score: 0.052
-
Crooks PA, Ayers JT, Xu R, Sumithran SP, Grinevich VP, Wilkins LH, Deaciuc AG, Allen DD, Dwoskin LP. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2004 Apr 19; 14(8):1869-74.
Score: 0.052
-
Ko K, Wei X, Crooks PA, Koprowski H. Elimination of alkaloids from plant-derived human monoclonal antibody. J Immunol Methods. 2004 Mar; 286(1-2):79-85.
Score: 0.052
-
Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors. J Pharmacol Exp Ther. 2003 Jan; 304(1):400-10.
Score: 0.048
-
Maggio SE, Saunders MA, Nixon K, Prendergast MA, Zheng G, Crooks PA, Dwoskin LP, Bell RL, Bardo MT. An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic a6?2* antagonist r-bPiDI. Drug Alcohol Depend. 2018 12 01; 193:154-161.
Score: 0.036
-
Beckmann JS, Siripurapu KB, Nickell JR, Horton DB, Denehy ED, Vartak A, Crooks PA, Dwoskin LP, Bardo MT. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. J Pharmacol Exp Ther. 2010 Dec; 335(3):841-51.
Score: 0.020
-
Grinevich VP, Crooks PA, Sumithran SP, Haubner AJ, Ayers JT, Dwoskin LP. N-n-alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther. 2003 Sep; 306(3):1011-20.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|